Codex
What's Next
HOLD at $10.48. Probability-weighted value is $10.35, about 1% below the April 9, 2026 close, so this is an income position rather than a fresh alpha setup. Keep sizing to 2% maximum until spread income is clearly back above the dividend or the stock resets closer to book.
Call
Prob-Weighted Value
Asymmetry Ratio
Max Position (%)
There is no standalone catalyst here besides quarterly proof. The annual meeting on April 16, 2026 is unlikely to move the stock unless management materially changes its dividend or capital-raising tone. The real event is the expected Q1 2026 release around April 20, 2026, followed by the April 21, 2026 stockholder presentation.
The local run does not include a forward Q1 2026 EPS consensus line, only historical quarterly estimates and surprises. The usable sell-side setup is the 12-month price-target range embedded in local research: roughly $10 to $13, with a $11.33 average. That is modest upside for a name whose payout cushion is still thin, which is why the market will watch book value and spread income more than reported GAAP revenue.
The Verdict
This is an equity hold, not a fresh buy. AGNC is not obviously broken, but the stock already prices a decent funding and spread regime while leaving little room for another earnings miss or a dividend reset. Cheap versus the yield is not the same thing as attractive versus path risk.
The valuation screen above is the core problem. At $10.48, AGNC already sits around the middle of a reasonable book-value and multiple grid. You do not need a disaster to lose money on price; you just need one or two more quarters where earnings stay thin and the premium-to-book multiple drifts back toward par.
What the market may be missing is simple: not much. This is a well-followed mortgage REIT, and the broad debate is already in the price. The usable edge is patience, not discovery. If AGNC trades back near or below book while coverage stabilizes, the exact same business becomes more interesting. At $10.48, that edge has mostly been consumed by the rerating.